Salute e Benessere

IBA - Regulated Information

Publication made under article 15 of the law of May 2, 2007 relating to the disclosure of major holdings in issuers whose shares are admitted to trading on a regulated market and containing various provisions ( Belgian Gazette 12.VI.2007) (hereinafter, the “Law”) Under this provision: "[...] the issuer publishes the total capital, the total number of securities conferring the right to vote and voting rights, as well as, by category, the number of securities conferring the...
Nasdaq GlobeNewswire
30/12/2024

Binding agreement signed between Icade and Casino

PRESS RELEASE Paris, December 30, 2024, 6:00 p.m.Casino Group signs a binding agreement to sell a property portfolio to Icade for €50mCasino Group has entered into a binding agreement to sell a portfolio of properties in 11 different locations to Icade Promotion for a selling price of €50 million.This portfolio consists of car parks, undeveloped land, premises and ancillary lots adjoining...
Nasdaq GlobeNewswire
30/12/2024

Renovaro Inc. Appoints Maurice van Tilburg to Lead GEDi Cube BV

Current Renovaro Chairman to Lead Subsidiary's Development Program and Commercialization LOS ANGELES and AMSTERDAM, Dec.30, 2024(GLOBE NEWSWIRE) --Renovaro Inc. (NASDAQ: RENB),a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced Chairman of the Board, Maurice van Tilburg, has been appointed as Chief Executive Officer of its subsidiaryGEDi Cube BV(a leader in AI-driven cancer diagnostics by integrating multi-omics with liquid...
Nasdaq GlobeNewswire
30/12/2024

Evaxion announces plan to implement ADS ratio change

/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that it plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares, DKK 1 nominal value (the “ADS ratio”), from the current one (1) ADS representing ten (10) ordinary share to a new ADS ratio of one (1) ADS representing fifty (50) ordinary shares (the “ADS ratio change”). The ADS ratio change is expected to become…
Nasdaq GlobeNewswire
30/12/2024

Orion and Marinus terminate agreement for ganaxolone in Europe

ORION CORPORATIONPRESS RELEASE30 DECEMBER 2024 at 14.00 EET Orion and Marinus terminate agreement for ganaxolone in EuropeOrion Corporation (“Orion”) and Marinus Pharmaceuticals, Inc. (“Marinus”) have decided to mutually terminate their European wide marketing and distribution agreement for ganaxolone. Marinus regains ganaxolone's commercial rights in Europe where the compound is approved for the adjunctive treatment of epileptic seizures associated with cyclin-dependent...
Nasdaq GlobeNewswire
30/12/2024

Orthodontics Meets Disney: Smartee Clear Aligners Brings Magic to Smiles

The Disney licensed products span both children's and adult clear aligners, catering to a wide range of patient needs. Additionally, Smartee has developed a series of Disney-themed orthodontic accessories, including water flossers, aligner cases, and ultrasonic aligner cleaners, bringing joy and practicality into the orthodontic care routine. These products not only elevate the treatment experience but also reflect Disney's core value of happiness in every aspect of the user's daily life. The...
PR Newswire
30/12/2024

MOVA launches Innovative products in Turkey.

S20 Ultra – MOVA's representative product S20 Ultra – MOVA's representative product It delivering exceptional cleaning power with features such as a Twin Rubber Brush, VibroTurbo Mopping System, and RoboSwing Mopping Technology. It boasts an impressive 8300Pa suction power* and a 60°C hot water* mop self-cleaning function for a superior cleaning performance. The S20 Ultra also integrates a smart cleaning strategy, which includes Main Brush & Intelligent Mop Lifting, Advanced Route...
PR Newswire
30/12/2024

Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary…

Ad hoc announcement pursuant to Art. 53 LR The Phase III STEER study met its primary endpoint showing an increase from baseline in HFMSE total score in patients with SMA treated with intrathecal onasemnogene abeparvovec (OAV101 IT)OAV101 IT is the first investigational gene therapy to provide clinical benefit in treatment-naïve patients with SMA aged two and older with a positive risk benefit profileNovartis plans to share results with regulatory agencies in 2025 with the aim to...
Nasdaq GlobeNewswire
30/12/2024

Maypharm Unveils Revolutionary Hybrid Filler, Hyalmass Aqua-Exosome: The Future…

Hyalmass Aqua-Exosome is a breakthrough in aesthetic innovation, offering unmatched benefits for skin health and rejuvenation. Unlike traditional hydration fillers that focus solely on moisture, Hyalmass Aqua-Exosome elevates skin health standards by leveraging the regenerative potential of exosomes and PDRN. Hyalmass Aqua-Exosome is a breakthrough in aesthetic innovation, offering unmatched benefits for skin health and rejuvenation. Unlike traditional hydration fillers that focus solely on...
PR Newswire
30/12/2024

Immunovia announces determined exercise price for warrants series TO 2 and…

"Securing the TO2 warrants on reasonable terms reduces risk and enables us to achieve key milestones. The proceeds from the exercise of the TO2 warrants will fund preparations to introduce our next-generation test to the US market in the second half of 2025. This capital will also support clinical studies to bolster our efforts to obtain reimbursement for the test." "Securing the TO2 warrants on reasonable terms reduces risk and enables us to achieve key milestones. The proceeds…
PR Newswire
28/12/2024

SAFE GROUP - Half-Year Financial Report as of June 30, 2024

HALF-YEAR FINANCIAL REPORT AS OF JUNE 30, 2024December 27, 2024, 6.00 p.m.Safe Group announces that it has made available to the public and filed with the Autorité des Marchés Financiers its half-year financial report as of June 30, 2024.The 2024 Half-Year Financial Report can be found onwww.safegrp.comwebsite in the Investors –Documentations section. About Safe Group Safe Group is a French medical technology group that brings together Safe Orthopaedics, a pioneer in...
Nasdaq GlobeNewswire
27/12/2024

Today the subscription period in SciBase rights issue begins

Summary of the Rights Issue Summary of the Rights Issue Prospectus For complete information about the Rights Issue, investors are referred to the published EU growth prospectus (the " Prospectus ", Swe.EU-Tillväxtprospekt ) which is available on SciBase's website ( https://investors.scibase.se/en/mid-disclaimer/107/83 ) and on Carnegie's website ( www.carnegie.se ). The Prospectus is also available on the Swedish Financial Supervisory Authority's website (...
PR Newswire
27/12/2024

Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment

The article continued: The oncology field continues to advance, with MarketsAndMarkets forecasting the Artificial Intelligence in Oncology Market to reach $11.52 billion by 2030, driven by a 29.4% CAGR. Similarly, Nova Advisor predicts the Personalized Cell Therapy Market will grow at a 23.53% CAGR, reaching $251.37 billion by 2034. The article continued: The oncology field continues to advance, withMarketsAndMarketsforecasting theArtificial Intelligence in Oncology Marketto reach$11...
PR Newswire
26/12/2024

Northwest Biotherapeutics Announces $5 Million Convertible Note Financing and…

Joseph Gunnar & Co., LLC acted as the exclusive placement agent for the offering. Joseph Gunnar& Co., LLC acted as the exclusive placement agent for the offering. About Northwest Biotherapeutics Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products that are designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis...
PR Newswire
26/12/2024

Microtech Announces First Human Case of Implantable Microsensor for Heart…

Speaking about the promise of Microtech's sensor platform, Prof. Sharoni, Head of Cardio-Thoracic Surgery, said, "This amazing technology may change the standard of care for patients suffering from Heart Failure and in particular, in this current study, those who are receiving LVADs or heart transplants." Speaking about the promise of Microtech's sensor platform, Prof. Sharoni, Head of Cardio-Thoracic Surgery, said, "This amazing technology may change the standard of care for…
PR Newswire
26/12/2024

Momcozy Unveils Winners of "Love in Action" Charity Contest, Emphasizing…

Let There Be Mom, the $10,000 second-place recipient, focuses on preserving the legacies of parents facing life-threatening illnesses, ensuring their children always have a means to remember them. Kipra Anderson, the Founder & Executive Director, noted, "Momcozy's dedication to supporting mothers and empowering crisis assistance organizations is evident." Let There Be Mom, the$10,000second-place recipient, focuses on preserving the legacies of parents facing life-threatening…
PR Newswire
26/12/2024

Smartee Expands Middle East Presence, Showcases Innovative Clear Aligner…

With a rising demand for clear aligners in emerging markets, especially the Middle East, Smartee is positioning itself at the forefront of this growth. Social media platforms like Instagram and TikTok are fueling the popularity of clear aligners by educating patients, while demand in Saudi Arabia, one of the region's largest markets, continues to rise. With a rising demand for clear aligners in emerging markets, especially theMiddle East, Smartee is positioning itself at the forefront of this…
PR Newswire
26/12/2024

Transactions in Zealand Pharma shares and/or related securities by persons…

Company announcement – No. 53 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, December 25, 2024–Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand Pharma's...
Nasdaq GlobeNewswire
25/12/2024

Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.

Company announcement – No. 52 / 2024 Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc. Copenhagen, Denmark, 25 December 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today reports receipt on 23 December 2024 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major...
Nasdaq GlobeNewswire
25/12/2024

European Wellness Biomedical Group Announces New Klotho Research Initiative Led…

"Klotho represents the next frontier in longevity medicine," said Professor Mike Chan, Chief Scientist at EWBG. "Our research aims to understand how Klotho affects aging and how we can use it to treat chronic diseases that have long been associated with aging." "Klotho represents the next frontier inlongevity medicine," saidProfessorMike Chan , Chief Scientist at EWBG. "Our research aims to understand how Klotho affects aging and how we can use it to treat…
PR Newswire
25/12/2024

Designs For Health Inc. Held Liable For Infringement of Kaneka's Ubiquinol…

"We are pleased that Judge Bryson has vindicated Kaneka's position that the '080 Patent was both infringed and valid" said Mr. Kazuhiko Fujii, President of Kaneka. "This victory is tangible proof of Kaneka's resolve to fully enforce its patent rights, including its patents covering ubiquinol. The protection of Kaneka's patent rights is paramount to Kaneka's business. Kaneka's commitment to protecting these rights is unwavering." "We are pleased that Judge Bryson has…
PR Newswire
24/12/2024

Global Multiomics Market Expected to Grow Rapidly, with 13.5% Annual Increase…

In this report, the global multiomics market is segmented by product, platform, application, end-user, and region. It includes market estimates from 2023 to 2029, for the region of North America, Europe, Asia-Pacific, and Rest of the World. The report discusses the major companies, market dynamics, and geographic opportunities and incorporates analytical frameworks such as PESTEL and ESG to provide a competitive analysis. Strategic recommendations are also provided to help companies devise…
PR Newswire
24/12/2024

LG'S LATEST INDOOR GARDENING APPLIANCE SHOWS OFF FRESH NEW DESIGN AT CES 2025

Slender and upright with a circular "lampshade" and base, LG's distinctive appliance is both an elegant interior object and a highly practical means of producing fresh home-grown greens. Despite its apartment-friendly footprint, the new model offers more growing space compared to the company's previous indoor gardening appliances, enabling users to nurture a wider variety of plants, including taller species. Its adaptable growing space and height-adjustable LED growing lights provide…
PR Newswire
24/12/2024

AIMA Technology Group to Showcase Seven Groundbreaking Products at CES 2025 and…

During CES 2025, AIMA Technology Group will hold a media reception on Tuesday, January 7th at 10:30 AM (Pacific Time) to showcase its new product lineup. On January 8th at 11:00 AM, AIMA will unveil the mysterious limited-edition concept product at the CES booth, redefining the future of mobility. We invite you to join us in discovering this groundbreaking innovation. Booth location: Las Vegas Convention Center, North Hall, Booth #10947, showcasing our latest innovative achievements. During…
PR Newswire
24/12/2024
Altri  Comunicati